Conference data: Seavue head to head study of ustekinumab and adalimumab in Crohn's disease

Study (n=386) found no significant difference in clinical remission at one year with ustekinumab and adalimumab (64.9% vs 61% achieved Crohn's Disease Activity Index [CDAI] <150) although discontinuation rates were lower with ustekinumab (15.2% vs 23.6%).

Source:

Biospace Inc.